Shots:

• The US FDA approved Vocabria (30mg- tablet formulation) in combination with oral rilpivirine (Edurant) for one month prior to starting treatment with Cabenuva to ensure the medications are well-tolerated before switching to the extended-release injectable formulation
• Additionally- changes to the Edurant (rilpivirine) tablet label were revised to reflect the oral lead-in recommendations for use with Vocabria
• The oral therapy is for the patients who will miss planned injection dosing with Cebenuva

­ Ref: FDA | Image: ViiV Healthcare